The global onychomycosis market is expected to reach USD 4.92 billion by 2030, expanding at a CAGR of 4.56% from 2022 to 2030. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.
Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.
International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.
Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.
This product will be delivered within 1-3 business days.
Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.
International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.
Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.
Onychomycosis Market Report Highlights
- Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
- Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
- Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
- North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Onychomycosis Market: Methodology And Scope1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 List Of Secondary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.10 List Of Abbreviations
Chapter 2 Onychomycosis Market: Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Onychomycosis Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Increasing Incidence Of Onychomycosis And Chronic Diseases
3.3.1.2 Rising Awareness About Treatment Of Onychomycosis
3.3.1.3 Escalating R&D Efforts By Players
3.3.1.4 Growing Geriatric Population And Diabetic Population
3.3.2 Market Restraint Analysis
3.3.2.1 Increasing Resistance To Antifungal Drugs
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Onychomycosis Market: Competitive Landscape
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Onychomycosis Market: Type Business Analysis
5.1 Definition And Scope
5.2 Type Market Share Analysis, 2022 & 2030
5.3 Global Onychomycosis Market, By Type, 2018 To 2030
5.4 Onychomycosis Market: Type Movement Analysis
5.5 Distal Subungual Onychomycosis
5.5.1 Distal Subungual Onychomycosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.6 White Superficial Onychomycosis
5.6.1 White Superficial Onychomycosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.7 Proximal Subungual Onychomycosis
5.7.1 Proximal Subungual Onychomycosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.8 Other Types
5.8.1 Other Types Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Onychomycosis Market: Treatment Business Analysis
6.1 Definition And Scope
6.2 Treatment Market Share Analysis, 2022 & 2030
6.3 Global Onychomycosis Market, By Treatment, 2018 To 2030
6.4 Tuberculosis Therapeutics Market: Treatment Movement Analysis
6.5 Oral
6.5.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.6 Topical
6.6.1 Topical Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.7 Others
6.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Onychomycosis Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
7.7 North America
7.7.1 North America Onychomycosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Onychomycosis Market, 2018 - 2030 (USD Million)
7.7.2.2 Key Country Dynamics
7.7.2.3 Regulatory Framework
7.7.2.4 Competitive Scenario
7.7.2.5 Import Export Scenario
7.7.2.6 Investments Scenario
7.7.3 Canada
7.7.3.1 Canada Onychomycosis Market, 2018 - 2030 (USD Million)
7.7.3.2 Key Country Dynamics
7.7.3.3 Regulatory Framework
7.7.3.4 Competitive Scenario
7.7.3.5 Import Export Scenario
7.7.3.6 Investments Scenario
7.8 Europe
7.8.1 Europe Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.2.2 Key Country Dynamics
7.8.2.3 Regulatory Framework
7.8.2.4 Competitive Scenario
7.8.2.5 Import Export Scenario
7.8.2.6 Investments Scenario
7.8.3 Germany
7.8.3.1 Germany Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.3.2 Key Country Dynamics
7.8.3.3 Regulatory Framework
7.8.3.4 Competitive Scenario
7.8.3.5 Import Export Scenario
7.8.3.6 Investments Scenario
7.8.4 Spain
7.8.4.1 Spain Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.4.2 Key Country Dynamics
7.8.4.3 Regulatory Framework
7.8.4.4 Competitive Scenario
7.8.4.5 Import Export Scenario
7.8.4.6 Investments Scenario
7.8.5 France
7.8.5.1 France Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.5.2 Key Country Dynamics
7.8.5.3 Regulatory Framework
7.8.5.4 Competitive Scenario
7.8.5.5 Import Export Scenario
7.8.5.6 Investments Scenario
7.8.6 Italy
7.8.6.1 Italy Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.6.2 Key Country Dynamics
7.8.6.3 Regulatory Framework
7.8.6.4 Competitive Scenario
7.8.6.5 Import Export Scenario
7.8.6.6 Investments Scenario
7.8.7 Russia
7.8.7.1 Russia Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.7.3 Regulatory Framework
7.8.7.4 Competitive Scenario
7.8.7.5 Import Export Scenario
7.8.7.6 Investments Scenario
7.8.8 Denmark
7.8.8.1 Denmark Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.8.2 Key Country Dynamics
7.8.8.3 Regulatory Framework
7.8.8.4 Competitive Scenario
7.8.8.5 Import Export Scenario
7.8.8.6 Investments Scenario
7.8.9 Sweden
7.8.9.1 Sweden Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.9.2 Key Country Dynamics
7.8.9.3 Regulatory Framework
7.8.9.4 Competitive Scenario
7.8.9.5 Import Export Scenario
7.8.9.6 Investments Scenario
7.8.10 Norway
7.8.10.1 Norway Onychomycosis Market, 2018 - 2030 (USD Million)
7.8.10.2 Key Country Dynamics
7.8.10.3 Regulatory Framework
7.8.10.4 Competitive Scenario
7.8.10.5 Import Export Scenario
7.8.10.6 Investments Scenario
7.9 Asia Pacific
7.9.1 Asia-Pacific Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.2.2 Key Country Dynamics
7.9.2.3 Regulatory Framework
7.9.2.4 Competitive Scenario
7.9.2.5 Import Export Scenario
7.9.2.6 Investments Scenario
7.9.3 China
7.9.3.1 China Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.3.2 Key Country Dynamics
7.9.3.3 Regulatory Framework
7.9.3.4 Competitive Scenario
7.9.3.5 Import Export Scenario
7.9.3.6 Investments Scenario
7.9.4 India
7.9.4.1 India Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.4.2 Key Country Dynamics
7.9.4.3 Regulatory Framework
7.9.4.4 Competitive Scenario
7.9.4.5 Import Export Scenario
7.9.4.6 Investments Scenario
7.9.5 South Korea
7.9.5.1 South Korea Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.5.2 Key Country Dynamics
7.9.5.3 Regulatory Framework
7.9.5.4 Competitive Scenario
7.9.5.5 Import Export Scenario
7.9.5.6 Investments Scenario
7.9.6 Thailand
7.9.6.1 Thailand Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.6.2 Key Country Dynamics
7.9.6.3 Regulatory Framework
7.9.6.4 Competitive Scenario
7.9.6.5 Import Export Scenario
7.9.6.6 Investments Scenario
7.9.7 Australia
7.9.7.1 Australia Onychomycosis Market, 2018 - 2030 (USD Million)
7.9.7.2 Key Country Dynamics
7.9.7.3 Regulatory Framework
7.9.7.4 Competitive Scenario
7.9.7.5 Import Export Scenario
7.9.7.6 Investments Scenario
7.10 Latin America
7.10.1 Latin America Onychomycosis Market, 2018 - 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Onychomycosis Market, 2018 - 2030 (USD Million)
7.10.2.2 Key Country Dynamics
7.10.2.3 Regulatory Framework
7.10.2.4 Competitive Scenario
7.10.2.5 Import Export Scenario
7.10.2.6 Investments Scenario
7.10.3 Mexico
7.10.3.1 Mexico Onychomycosis Market, 2018 - 2030 (USD Million)
7.10.3.2 Key Country Dynamics
7.10.3.3 Regulatory Framework
7.10.3.4 Competitive Scenario
7.10.3.5 Import Export Scenario
7.10.3.6 Investments Scenario
7.10.4 Argentina
7.10.4.1 Argentina Onychomycosis Market, 2018 - 2030 (USD Million)
7.10.4.2 Key Country Dynamics
7.10.4.3 Regulatory Framework
7.10.4.4 Competitive Scenario
7.10.4.5 Import Export Scenario
7.10.4.6 Investments Scenario
7.11 MEA
7.11.1 MEA Onychomycosis Market, 2018 - 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Onychomycosis Market, 2018 - 2030 (USD Million)
7.11.2.2 Key Country Dynamics
7.11.2.3 Regulatory Framework
7.11.2.4 Competitive Scenario
7.11.2.5 Import Export Scenario
7.11.2.6 Investments Scenario
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia Onychomycosis Market, 2018 - 2030 (USD Million)
7.11.3.2 Key Country Dynamics
7.11.3.3 Regulatory Framework
7.11.3.4 Competitive Scenario
7.11.3.5 Import Export Scenario
7.11.3.6 Investments Scenario
7.11.4 UAE
7.11.4.1 UAE Onychomycosis Market, 2018 - 2030 (USD Million)
7.11.4.2 Key Country Dynamics
7.11.4.3 Regulatory Framework
7.11.4.4 Competitive Scenario
7.11.4.5 Import Export Scenario
7.11.4.6 Investments Scenario
7.11.5 Kuwait
7.11.5.1 Kuwait Onychomycosis Market, 2018 - 2030 (USD Million)
7.11.5.2 Key Country Dynamics
7.11.5.3 Regulatory Framework
7.11.5.4 Competitive Scenario
7.11.5.5 Import Export Scenario
7.11.5.6 Investments Scenario
Chapter 8 Onychomycosis Market: Company Profiling
8.1 Company Profiles
8.1.1 Bausch Health Companies Inc.,
8.1.1.1 Company Overview
8.1.1.2 Financial Performance
8.1.1.3 Product Benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 Gsk Plc
8.1.2.1 Company Overview
8.1.2 2.Financial Performance
8.1.2.3 Product Benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 Abbott
8.1.3.1 Company Overview
8.1.3.2 Financial Performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 F. Pfizer Inc.,
8.1.4.1 Company Overview
8.1.4.2 Financial Performance
8.1.4.3 Product Benchmarking
8.1.4.4 Strategic Initiatives
8.1.5 Bayer Ag
8.1.5.1 Company Overview
8.1.5.2 Financial Performance
8.1.5.3 Product Benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 Teva Pharmaceutical Industries, Ltd.
8.1.6.1 Company Overview
8.1.6.2 Financial Performance
8.1.6.3 Product Benchmarking
8.1.6.4 Strategic Initiatives
8.1.7 Cipla Inc.
8.1.7.1 Company Overview
8.1.7.2 Financial Performance
8.1.7.3 Product Benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 Novartis Ag
8.1.8.1 Company Overview
8.1.8.2 Financial Performance
8.1.8.3 Product Benchmarking
8.1.8.4 Strategic Initiatives
8.1.9 Sun Pharmaceutical Industries Ltd.
8.1.9.1 Company Overview
8.1.9.2 Financial Performance
8.1.9.3 Product Benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 Merck & Co., Inc.
8.1.10.1 Company Overview
8.1.10.2 Financial Performance
8.1.10.3 Product Benchmarking
8.1.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Onychomycosis Market, By Region, 2018 - 2030 (USD Million)
Table 5 North America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 7 North America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 8 U.S. Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 9 U.S. Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 10 Canada Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 11 Canada Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 12 Europe Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 13 Europe Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 14 Europe Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 15 Germany Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 16 Germany Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 17 U.K. Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 18 U.K. Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 19 France Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 20 France Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 21 Italy Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 22 Italy Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 23 Spain Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 24 Spain Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 25 Denmark Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 26 Denmark Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 27 Sweden Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 28 Sweden Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 29 Norway Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 30 Norway Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 31 Asia Pacific Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Onychomycosis Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Japan Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 35 Japan Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 36 China Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 37 China Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 38 India Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 39 India Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 40 South Korea Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 41 South Korea Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 42 Australia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 43 Australia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 44 Thailand Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 45 Thailand Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 46 Latin America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 47 Latin America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 48 Latin America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 49 Brazil Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 50 Brazil Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 51 Mexico Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 52 Mexico Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 53 Argentina Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 54 Argentina Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 60 South Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 61 South Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 62 UAE Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 63 UAE Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 64 Kuwait Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 65 Kuwait Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Onychomycosis Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration & Growth Prospect Mapping
Fig. 15 Onychomycosis market: Type outlook and key takeaways
Fig. 16 Onychomycosis market: Type movement analysis & market share 2022 & 2030
Fig. 17 Distal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 White superficial onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Proximal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Onychomycosis market: Treatment outlook and key takeaways
Fig. 22 Onychomycosis market: Treatment movement analysis & market share 2022 & 2030
Fig. 23 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Regional Marketplace: Key Takeaways
Fig. 27 Regional Outlook, 2022 & 2030
Fig. 28 Regional Market Dashboard
Fig. 29 Regional Market Place: Key Takeaways
Fig. 30 North America, SWOT Analysis
Fig. 31 Europe, SWOT Analysis
Fig. 32 Asia Pacific, SWOT Analysis
Fig. 33 Latin America, SWOT Analysis
Fig. 34 MEA, SWOT Analysis
Fig. 35 North America
Fig. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 37 U.S.
Fig. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 39 Canada
Fig. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 41 Europe
Fig. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 43 U.K.
Fig. 44 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 45 Germany
Fig. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 47 France
Fig. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 49 Italy
Fig. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 51 Spain
Fig. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 53 Denmark
Fig. 54 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 55 Sweden
Fig. 56 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 57 Norway
Fig. 58 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 59 Asia Pacific
Fig. 60 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 61 Japan
Fig. 62 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 63 China
Fig. 64 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 65 India
Fig. 66 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 67 Australia
Fig. 68 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 69 Thailand
Fig. 70 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 71 South Korea
Fig. 72 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 73 Latin America
Fig. 74 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 75 Brazil
Fig. 76 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 77 Mexico
Fig. 78 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 79 Argentina
Fig. 80 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 81 MEA
Fig. 82 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 83 South Africa
Fig. 84 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 85 Saudi Arabia
Fig. 86 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 87 UAE
Fig. 88 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 89 Kuwait
Fig. 90 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 91 Strategy Mapping
Companies Mentioned
- Bausch Health Companies Inc.,
- Gsk Plc
- Abbott
- F. Pfizer Inc.,
- Bayer Ag
- Teva Pharmaceutical Industries, Ltd.
- Cipla Inc.
- Novartis Ag
- Sun Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 3.44 Billion |
| Forecasted Market Value ( USD | $ 4.92 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
